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ABSTRACT 
Cardiovascular calcification is a pathophysiological process characterized by the deposition 
of calcium-phosphate crystals in the arteries and the leaflets of the heart valves. In the arteries 
calcification causes arterial stiffness, which may lead to poor cardiac perfusion, systolic 
hypertension and heart failure. In the aortic valve, calcification causes left ventricular outflow 
obstruction. Currently, no medical treatment exists to halt or reverse cardiovascular 
calcification. For that reason, understanding the molecular mechanisms underlying 
cardiovascular calcification is of particular importance. 
Molecularly, cardiovascular calcification is a continuum comprising intertwined 
physicochemical and biologically active processes. In particular, cardiovascular calcification 
commences when cells become overburdened by the mineral imbalance typical of chronic 
kidney disease (CKD), or the unresolved inflammation characteristic of atherosclerosis and 
aortic valve stenosis (AVS). These alterations in homeostasis lead to changes in the fate and 
phenotype of structural cells such as vascular smooth muscle cells (VSMCs) and valvular 
interstitial cells (VICs). This phenotypic switch is characterized by: the loss of calcification 
inhibitors, an increase in pro-osteogenic signaling, changes in proliferation, abnormal 
processing and synthesis of extracellular matrix (ECM), and alterations in autophagy.  
In the current thesis, three pathways relevant to cardiovascular calcification are discussed. 
First, in Articles I and II, the G-protein coupled receptor ChemR23 arises as a promoter of a 
synthetic and proliferative VSMC phenotype, prone to phosphate-induced calcification. 
Importantly, this phenotype could be reverted by genetic deletion of ChemR23, and 
calcification was inhibited by the ChemR23 ligands: RvE1 and chemerin. Translationally, 
chemerin was negatively associated with coronary artery calcification in CKD patients. 
Moreover, in Article III, ChemR23 expressed in macrophages, promoted the resolution of 
inflammation, and inhibited VSMC proliferation in a mouse model of intimal hyperplasia. 
Secondly, Article IV demonstrates that iron, preferentially present in the calcified regions of 
the aortic valve, accumulated in VICs. This uptake of iron enhanced VIC proliferation and 
actively contributed to the ECM remodeling. Finally, Article V reveals a detrimental role of 
the second generation tyrosine kinase inhibitor nilotinib on the aortic valve. In vivo, nilotinib 
promoted aortic valve thickening. In vitro, nilotinib enhanced VIC osteoblastic trans-
differentiation, increased calcification and inhibited autophagy. Mechanistically, nilotinib 
preferentially inhibited the most abundant collagen sensing tyrosine kinase in the valve: the 
discoidin domain receptor 2. 
Overall the results from this thesis suggests that changes in VSMC and VIC phenotype, as 
well as alterations in the ECM content and sensing can have profound effects on 
cardiovascular calcification, and therefore serve as potential therapeutic targets. 
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1 INTRODUCTION 
1.1 Cardiovascular Calcification 
Cardiovascular calcification results from the nucleation of calcium and phosphate into 
calcium-phosphate crystals in the arteries and the leaflets of the heart valves. Cardiovascular 
calcification is the consequence of three non-mutually exclusive processes: dystrophic 
calcification, metastatic calcification and heterotopic ossification. Dystrophic calcification is 
defined as the deposition of calcium and phosphate crystals in soft tissues as a result of 
injury, disease, and age.  On the other hand, in metastatic calcification the deposition of 
calcium and phosphate occurs in healthy tissue as a consequence of hyperphosphatemia and 
hypercalcemia 1. Finally, heterotopic ossification is the organized biomineralization of soft 
tissue, which exhibits a similar structure as mature bone 2, 3. 
1.1.1 Vascular Calcification 
Vascular calcification can occur in different locations of the arteries depending on the disease 
etiology. Arteries are formed by an outermost layer, known as the adventitia; a medial layer, 
known as the media; and an innermost layer in contact with the blood, known as the intima. 
The outermost layer, the adventitia, is composed of fibroblasts, connective tissue, and 
adipocytes. The adventitia serves as support for the vessels, but also as a niche for 
mesenchymal stem cells (MSCs). Adventitial MSCs have been implicated in both intimal and 
medial calcification by serving as a source of osteoblast-like cells 4. Interestingly, recent 
reports have shown calcification in the adventitia of ApoE-deficient mice (ApoE-/-) fed a high 
fat diet and autopsy samples of patients who had died of heart failure or acute renal failure 5. 
The second layer, the media, is composed of elastin fibers and vascular smooth muscle cells 
(VSMCs). Under physiological conditions VSMCs are responsible for maintaining a variable 
contractile tone of the arteries. To achieve this, a wide variety of contractile proteins are 
expressed, such as actin (ACTA2), calponin (CNN1) and smooth muscle cell protein 22-
alpha (SM22A). In addition, VSMCs present a high plasticity, which allows them to undergo 
diverse phenotypic changes, which will be discussed later in detail.   
Medial calcification is most prevalent in diabetes and chronic kidney disease (CKD). CKD 
refers to the gradual loss of kidney structure and function, which translates in the build-up of 
phosphate (hyperphosphatemia), calcium (hypercalcemia) and uremic toxins in the blood 6. 
Medial calcification causes arterial stiffness, which may lead to poor cardiac perfusion, 
systolic hypertension and heart failure 7.  
The innermost layer, in direct contact with the blood is the intima, which is composed of a 
monolayer of endothelial cells. This monolayer acts as a selective barrier for cells and 
molecules, which regulate the vascular tone as well as coagulation and fibrinolysis. In the 
context of vascular calcification endothelial cells can produce bone morphogenic proteins 
(BMPs), which are inducers of calcification 8. Moreover, endothelial cells undergo an 
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endothelial-mesenchymal transition, thus becoming osteogenic cells 9. Intimal calcification is 
characteristic of atherosclerosis. Atherosclerosis is a chronic inflammatory disease 
characterized by cholesterol accumulation, macrophage infiltration, as well as VSMC 
migration and proliferation into the intima layer of the arterial wall, known as the 
atherosclerotic plaque. It is under these conditions, and in this location, where intimal 
calcification takes place. Calcification of coronary atherosclerotic plaques, in the form of 
spotty micro calcifications, decrease plaque stability, thus increasing the risk of plaque 
rupture, thrombus formation, and subsequent myocardial infarction 10 11. 
Initially calcification is driven by the presence of inflammatory cytokines and oxidized lipids 
which promote endothelial activation as well as VSMCs trans-differentiation and apoptosis 
12. One key difference between medial and intimal calcification is that intimal calcification 
can occur in the absence of hyperphosphatemia due to the strong inflammatory environment 
6. Under inflammation an important source of phosphate comes from the hydrolysis of ATP 
by the tissue non-specific alkaline phosphatase (TNAP) 13. Moreover, in intimal calcification, 
unlike medial calcification, macrophages accumulate. These macrophages, secrete matrix 
vesicles and matrix metalloproteinases (MMPs) which facilitate the deposition of calcium-
phosphate crystals 14. 
1.1.2 Valvular Calcification 
Calcification of the aortic valve is known as aortic valve sclerosis. When aortic valve 
calcification causes left ventricular outflow obstruction, it is referred to as aortic valve 
stenosis (AVS). AVS is a common disease, with a prevalence of 2-7% in populations above 
65 years 15. The incidence and severity of AVS increase with age 16, as well as with several 
cardiovascular risk factors such as: obesity 17, smoking 18, and renal dysfunction 19. AVS is a 
progressive disease with a 1-year mortality of almost 50% in patients with symptomatic AVS 
20, 21. Currently no medical treatment exists to stop the calcification process in the 
cardiovascular system. With either surgical valve replacement or, transcatheter aortic valve 
implantation as the only alternatives for AVS patients. 
The aortic valve is composed of a monolayer of valvular endothelial cells (VECs), in direct 
contact with the blood, on both the aortic and ventricular side. These endothelial cells serve 
as sensors of hemodynamic forces. In between these two layers, three distinct layers of 
extracellular matrix and valvular interstitial cells (VICs) form the bulk of the valve. Closer to 
the aortic side is the fibrosa, formed by VICs and collagen. The middle layer is the spongiosa, 
composed of VICs and glycosaminoglycans. Finally, closest to the ventricular side is the 
ventricularis, formed of VICs and elastin 22. VICs are the most abundant cell type in the 
valve. VIC are phenotypically and functionally diverse. The most abundant population is the 
pleomorphic fibroblastic VIC, which produce different extracellular matrix (ECM) 
components and growth factors; and lack myofilaments23.  
At the initial stages of the disease mechanical stress, inflammatory molecules and lipids 
damage the endothelium, allowing lipids and immune cells to infiltrate, thus promoting 
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thickening and calcification of the valve. Another mechanism of AVS progression discussed 
in the current thesis is the extravasation of red blood cells inside the valve called intraleaflet 
haemorrhage, which occurs as a consequence of endothelial microfissuring 24 and rupture of 
neovessels 25. 
1.2 Molecular Mechanisms of Vascular Calcification 
Cardiovascular calcification is a pathophysiological continuum comprising intertwined 
physicochemical and biologically active processes. The temporality of events leading to 
cardiovascular calcification remains to be fully elucidated; however, the calcification process 
can be divided in two intertwined steps: the loss of calcification inhibitors and changes in the 
phenotype of structural cells.  
Initially, cardiovascular calcification commences when cells become overburdened by the 
mineral imbalance typical of CKD, or the unresolved inflammation characteristic of 
atherosclerosis and AVS. The excess of calcium, phosphate and uremic toxins, in CKD, and 
the infiltration of lipids and immune cells in atherosclerosis and AVS promote the 
proliferative and synthetic phenotype of structural cells 26. This phenotypic switch is 
characterized by: the loss of calcification inhibitors both systemically and locally 27-29; an 
increase in the pro-osteogenic BMP-2; the subsequent upregulation of TNAP 30; changes in 
proliferation; and the abnormal processing of ECM components, such as the degradation of 
elastin 31, 32. The combination of these factors is essential for the initial precipitation, 
nucleation and growth of calcium-phosphate crystals. Especially since the precipitation of 
calcium and phosphate, under normophosphatemia and the presence of calcification 
inhibitors, is not thermodynamically favored 33, 34. Next, these crystals promote the 
phenotypic switch of VSMCs and VICs into osteoblast like cells. These osteoblasts like cells 
are responsible for the heterotopic bone formation characteristic of the later stages of vascular 
calcification, present in 10% to 13% of the calcified valves and arteries 2, 3, 35. The key 
molecules overexpressed during this osteoblastic trans-differentiation, and discussed in the 
current thesis, are the runt-related transcription factor 2 (Runx2) and collagen. The interplay 
between such processes will be discussed in the following section. 
1.2.1 Calcification Inhibitors 
Under homeostasis, the deposition of calcium and phosphate is actively inhibited by 
calcification inhibitors present in the circulation and produced locally by structural cells. 
Calcification inhibitors can act either by direct physicochemical inhibition of calcium-
phosphate crystals, or by inhibiting pro-calcifying molecules and pathways in cells 29.  Some 
of the most relevant inhibitors of calcification addressed in the present thesis include: matrix 
gla protein (MGP), osteoprotegerin (OPG), Fetuin-A and pyrophosphate (Ppi). 
MGP is a calcification inhibitor produced locally by VSMCs and chondrocytes. To exert its 
function, the glutamate residues in MGP need to be carboxylated by vitamin-K. When 
carboxylated, MGP can inhibit calcification by directly binding calcium ions as well as BMP-
2 36, thus inhibiting both the physicochemical and cell mediated calcification 30, 37. Genetic 
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deletion of MGP leads to extensive cardiovascular calcification in mice37. Interestingly, MGP 
knock-out mice backcrossed with hypophosphatemic mice (hyp mice) present no vascular 
calcification, which can be reverted by feeding these mice a high phosphate diet 38.  
OPG is a glycoprotein that inhibits osteoclastogenesis by acting as a decoy receptor for the 
receptor activator of nuclear factor-kappaB ligand (RANKL) 39. In the vasculature OPG has 
potent anti-calcifying effects both in vitro and in vivo, and OPG knock-out mice develop 
osteoporosis and vascular calcification. In the vasculature the inhibitory mechanisms involve 
RANKL inhibition, Notch1 inhibition, and cell survival 40, 41.   
Fetuin A (or α2-Heremans-Schmid glycoprotein), is a negative acute phase protein produced 
in the liver and downregulated with inflammation 42, which forms colloidal complexes with 
calcium and phosphate in plasma 43. These complexes, referred to as calciprotein particles 
(CPPs) inhibit growth of calcium-phosphate crystals in the blood and thereby prevent their 
soft tissue deposition. Interestingly, the development of cardiovascular calcification in the 
Fetuin A knock-out mice appears to be highly dependent on the strain 44, diet 43 and specially 
the kidney function 45. This suggests that fetuin A may prevent cardiovascular calcification 
only when the calcium phosphate balance is disturbed, whereas its protective effects under 
physiological conditions may be limited 46. 
Ppi is an inorganic molecule derived from the hydrolysis of ATP by the ectoenzyme 
nucleotide pyrophosphatase/phosphodiesterase-1 (eNPP1), and degraded by TNAP. Ppi 
inhibits calcification both in vitro and in vivo, by substituting phosphate thus preventing 
further mineralization 47. Importantly, both a lack of production, or increase in degradation of 
Ppi leads to vascular calcification 48. 
1.2.2 Structural Cell Phenotypic Trans-differentiation 
The structural cells that comprise both the aortic valve and the arteries, VICs and VSMCs 
respectively, are quiescent but highly plastic cells.  VICs and VSMCs can alter their fate by 
undergoing complex structural and functional changes. Some of these changes in cell fate 
which are discussed in the current thesis include: the synthetic and proliferative phenotype, 
the osteoblastic phenotype, and alterations in autophagy. 
1.2.2.1 Synthetic and proliferative phenotype 
In response to injury and inflammation, characteristic of percutaneous coronary interventions 
or coronary artery bypass grafting 49, VSMCs undergo phenotypical switching and de-
differentiation characterized by changes in proliferation, contractility and ECM production 50. 
Specifically, VSMCs increase their proliferation and undergo a downregulation of contractile 
proteins like ACTA2, CNN1 and SM22A. Importantly, high phosphate can also promote the 
downregulation of contractile proteins, through its transport by the type III NaPi 
cotransporters (PiT-1 and PiT-2), and intracellular signaling 27. On the other hand, as a 
consequence of lipid infiltration, pro-inflammatory cytokines and high phosphate VICs 
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proliferate. Moreover, in sharp contrast with VSMCs, VICs increase their expression of 
contractile proteins, resembling myofibroblasts, which express ACTA2, CNN, SM22A 51. 
Nonetheless, despite this fundamental difference, VICs and VSMCs undergo similar changes 
in the synthesis and degradation of the extracellular matrix (ECM). Therefore, this abnormal 
processing of the ECM is as a key step for the thickening and calcification of valves and 
arteries. Two ECM molecules, widely implicated in cardiovascular calcification, and studied 
in the current work are elastin and type I collagen.  
Type I collagen is a fibrillar protein which provides the three-dimensional framework for 
both mechanical strength and cellular signaling in arteries and heart valves 52.  Type I 
collagen is secreted by osteoblast during bone formation, serving as a scaffold for the 
deposition of phosphate and calcium ions 38. In the vessels, the vast majority of the calcium 
phosphate mineral deposits occurs within areas of collagen fibrils, but only a small portion of 
the calcification occurs on the collagen fibers as in bone 53. In the vasculature, collagen is 
produced by VSMCs under calcifying conditions and capable of entrapping calcifying 
molecules. Interestingly, in atherosclerotic plaques, mature collagen fibers surround large 
calcifications, whereas micro-calcifications locate in areas of low collagen density, within the 
gaps of the collagen fibers, rather than on the collagen. Importantly, genetic deletion of 
collagen degrading matrix metalloproteinase 13(MMP13) in mice, under a 
hypercholesterolemic background, leads to a decrease in calcification size, but not in total 
calcium content 54. In line with these observations, collagen inhibits VIC calcification 55, and 
its disruption promotes calcification and alteration in valve phenotype 56. This highlights the 
importance of collagen in the development of cardiovascular calcification.  
Mechanistically, collagen does not only serve as a physicochemically favorable scaffold for 
the deposition of calcium and phosphate, but also as a signaling molecule. Fibrillar collagens 
can signal through non-integrin tyrosine kinase receptors, known as discoidin domain 
receptors 1 and 2 (DDR1/2). These receptors are involved in cell to collagen interactions, 
implicated in cell migration, proliferation, differentiation, and survival. Specifically in 
VSMCs, DDRs are implicated in collagen remodeling 57 and more recently DDR1 has been 
shown to regulate VSMC mediated calcification and fibrosis 58. Taken together, both collagen 
and its sensing arise as key mechanisms in the regulation of cardiovascular calcification.  
Another key ECM protein, essential for the elasticity characteristic of arteries and the 
pliability of valves, is elastin (ELN). Hemizygosity in the ELN gene has been associated with 
supravalvular aortic stenosis, characteristic of Williams-Beuren syndrome; and deletion or 
hemizygosity in mice leads to increase blood pressure, VSMC proliferation and tortuous 
arterial development 59. In vitro, ELN degradation enhances calcification in VSMCs cultured 
with high phosphate 60. Importantly, in nephrectomized uremic mice, ELN degradation 
precedes calcification 32. In addition, elastolytic cathepsins are upregulated in AVS 61, and 
genetic ablation of the elastolytic enzyme cathepsin-S inhibits vascular and valvular 
calcification in nephrectomized mice with hypercholesterolemia 31. Interestingly, MGP 
knock-out mice present disrupted ELN, and the initial calcium and phosphate deposits occur 
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within these ELN fibers. In addition, MGP knock-out mice, hemizygous for ELN present 
decreased calcification 62. Taken together, ELN content and integrity appears essential in 
maintaining homeostasis of the cardiovascular system and its reduction and degradation 
enhances cardiovascular calcification. 
1.2.2.2 Osteoblastic phenotype 
Alongside the aforementioned changes in ECM and decrease in calcification inhibitors, 
another key event in the development of cardiovascular calcification is the osteoblastic trans-
differentiation, characterized by the upregulation of calcification inducers, which leads to the 
organized deposition of calcium-phosphate crystals 28, 63. Specifically, the main drivers of the 
osteoblastic trans-differentiation addressed in the current thesis are BMP-2 and Runx2. 
Among these calcification inducers one of the first to be upregulated is BMP-2 64, 65.  
BMP-2 belongs to the transforming growth factor beta (TGF-β) superfamily; essential in 
bone, cartilage and vascular development. BMP-2 signals through the bone morphogenetic 
protein receptor type 2 (BMPR2), which leads to the phosphorylation of SMAD 1/5/8 and 
subsequent transcriptional activation 66. In the vasculature BMP-2 is expressed in 
atherosclerotic plaques 64, and its overexpression in VSMCs enhances intimal calcification, 
but not total atherosclerotic plaque size in ApoE-/- mice 67. In line with these results, genetic 68 
and pharmacological 69 inhibition of BMP-2 signaling lead to a decrease in both intimal 
calcification and atherosclerosis formation.  In CKD patients, BMP-2 serum levels are higher 
than in control subjects 70. Mechanistically, BMP-2 is upregulated by high phosphate in 
VSMCs. Consequentially, BMP-2 decreases SM22A, increases Runx2 expression and 
increases TNAP activity in vitro 70-72. This suggests, that overexpression and lack of 
inhibition of BMP-2 correspond to the initial stages in the trans-differentiation of VMSCs and 
VICs leading to calcification. 
Together with an increase in BMP-2 signaling, cardiovascular calcification is characterized 
by an increase in Runx2 expression. Runx2, alongside the transcription factor SOX9, is a 
master regulator of skeletal development 73. In the cardiovascular system, nano-analytical 
electron microscopy has revealed that Runx2 is expressed in cells surrounding crystalline 
spherical particles, present in macroscopically and histologically healthy regions of human 
valves and vessels 53. However, despite being present early in the calcification process, 
calcium-phosphate crystals and BMP-2 appear to precede Runx2 expression 65. Nonetheless, 
Runx2 is essential for the calcification of the cardiovascular system. In VSMCs, Runx2 is 
necessary for the osteoblastic differentiation and mineralization both in vitro and in vivo 74. In 
fact, targeted deletion of Runx2 in VSMCs inhibits calcification in several mouse models of 
calcification 74, 75. Moreover, Runx2 has been proposed to be an inhibitor of VSMC markers, 
suggesting a key role in VSMC trans-differentiation and calcification 76. Overall, Runx2 
upregulation appears to be a consequence of initial calcification, but it is fundamental for the 
progression of calcification in the vasculature leading to the final stages in the trans-
differentiation of VMSCs and VICs towards an osteoblast like phenotype.   
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1.2.2.3 Autophagy & Apoptosis 
Together with changes in cell phenotype, hyperphosphatemia and hypercalcemia can lead to 
VIC and VSMC apoptosis. Specifically, calcium promotes VSMC apoptosis and vesicle 
release, which in turn serve as nucleating structures for calcium and phosphate deposition. A 
pathway through which cells protect themselves from calcification is autophagy. Autophagy 
is a highly conserved mechanism involved in the recycling and catabolism of proteins 77. 
Recently, autophagy has been shown to be a protective mechanism, safeguarding VSMCs 
from phosphate induced calcification 78. In VICs, autophagy serves as an inhibitor of 
osteoblastic trans-differentiation 79, as well as a survival mechanism 80 ; its inhibition leads to 
increased calcification in VSMCs, and decreased viability in VICs. 
 
Figure 1. VSMC and VIC phenotypic trans-differentiation and cell fate: A) Under homeostasis VSMCs 
present a contractile phenotype. Under stress VSMCs can trans-differentiate into a synthetic or osteoblastic 
phenotype, as well as undergo apoptosis. B) Under homeostasis VICs present a quiescent phenotype. Under 
stress VICs can trans-differentiate into a myofibroblast or osteoblastic phenotype, as well as undergo apoptosis. 
1.3 Omega-3 and Vascular Calcification 
As previously alluded to, vascular calcification is preceded by apoptosis; the apoptotic cells 
and apoptotic bodies act as nucleating structures for calcium-phosphate crystal formation. 
Under physiological conditions, apoptotic cells in the vessel wall are removed by specialized 
macrophages, thus promoting the resolution of inflammation. However, failure in the 
resolution of inflammation, characteristic of atherosclerosis and aortic stenosis, favors the 
production of dystrophic calcification 81. 
Resolution of acute inflammation is an active process mediated by a diverse set of factors 
including but not limited to: cytokines (IL-10), cells (regulatory T cells), and lipid mediators. 
The latter represent a class of bioactive lipids produced endogenously that signal through G 
protein coupled receptors (GPCRs) and promote the resolution of inflammation. In particular, 
resolvins are bioactive lipid mediators derived from the omega-3 polyunsaturated fatty acids 
(PUFAs): eicosapentanoic acid (EPA), and docosahexaenoic acid (DHA)82. 
Administration of EPA to rats decreases warfarin-induced calcification, as well as 
macrophage infiltration 83. In addition, a recent report showed that dietary supplementation of 
EPA in klotho-deficient mice prevents vascular calcification without modification in 
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phosphate or calcium serum levels. In these mice, EPA modifies the expression and activity 
levels of NADPH oxidase, mediated by the receptor GPR120, however the effect of this 
receptor in calcification was not explored. Interestingly, the authors found increased resolvin 
E1 (RvE1), a lipid mediator derived from EPA, in the serum of EPA treated mice 84. 
Moreover, in humans, a prospective cohort study has shown that serum levels of omega-3 
PUFAs correlate with lower incidence of coronary artery calcification 85. Taken together, 
these data show that omega-3 PUFAs reduce cardiovascular calcification; however, the 
mechanism of action remains elusive. 
Some work trying to elucidate the mechanism of action of DHA and EPA has been carried 
out using calcifying vascular cells (CVCs), a subpopulation of bovine aortic medial cells that 
undergo spontaneous osteoblast differentiation and calcification. Under this experimental 
conditions, DHA reduces osteoblastic differentiation, and TNAP. DHA promotes the 
phosphorylation of p38-mitogen-activated protein kinase (MAPK), alongside the activation 
of the peroxisome proliferator-activated receptor-γ (PPAR- γ)86. These experiments shed light 
on the potential pathways involved in the reduction of vascular calcification by omega-3 
PUFAs; however, they do not address whether these effects are mediated directly by DHA 
and EPA or their metabolites, or if these effects are receptor dependent or the consequence of 
changes in the membrane composition. 
Another piece of evidence helping us understand the mechanism by which omega-3 PUFAs 
act, in particular resolvins, has been obtained in osteoblasts. Osteoblast cultures treated with 
RvE1 increased OPG production under pro-inflammatory conditions, without modifying 
TNAP or Runx2. In the same study, the authors generated a transgenic mouse overexpressing 
the receptor for RvE1, the chemokine like receptor 1 (ChemR23). Transgenic mice showed a 
reduction in alveolar bone loss in an experimental model of periodontitis 87, suggesting that 
both the ChemR23 and its ligand have a protective role in bone metabolism. However, the 
role of ChemR23 in vascular calcification remains unexplored. 
1.3.1 ChemR23 and Bone/Cell Fate 
ChemR23 is a highly conserved GPCR coupled to intracellular calcium release, cAMP 
inhibition, and subsequent inhibition of ERK 1/2, through Gi/o subtype G proteins. ChemR23 
was originally described as the receptor for the chemoattractant protein chemerin but was 
later described as the receptor for RvE188, 89. 
Chemerin is an adipokine that requires proteolytic cleavage in order to exert its functions. 
The main source of chemerin in the body is visceral adipose tissue. Chemerin has been 
associated with obesity, insulin resistance, metabolic syndrome, and CKD90-94. However, 
paradoxically, in incident dialysis patients chemerin is associated with a survival advantage95. 
These discrepancies may be attributed to the fact that chemerin can exert both pro or anti-
inflammatory effects depending on the type of proteolytic cleavage carried out by proteases 
96. As a matter of fact, studies using both differentially cleaved chemerin and ChemR23 
knock-out mice suggest an anti-inflammatory role 97. Other possible explanations could 
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implicate the post-translational modifications of chemerin, signaling through the other 
chemerin receptors CCRL2 or GPR1, or ChemR23 heteromerization98-100. For these reasons it 
is important to understand which cells express ChemR23, as well as the general and cell 
specific functions that it exerts. 
ChemR23 is expressed in a wide variety of cells including: macrophages, dendritic cells, 
cytotoxic natural killer cells, chondrocytes, osteoblast, endothelial cells and VSMCs. In 
immune cells, ChemR23 acts as a chemoattractant upon chemerin binding inducing 
phagocytosis under RvE1 stimulation 97. 
In VSMCs, knock-down of ChemR23 decreased proliferation and migration, while 
stimulation with RvE1 decreases PDGF induced migration 100, 101. In contrast, chemerin 
promotes proliferation and migration, while antibody neutralization of chemerin reduces 
carotid ligation induced intima hyperplasia 102. This suggests that both the receptor and its 
ligands have an effect on VSMCs phenotype. 
Interestingly, the vasculature is not the only organ where ChemR23 appears to have a key 
role in cell fate. In 1997, ChemR23 was found to be present during bone development 103. 
More recently, the presence of ChemR23 in bone has been confirmed in mouse calvarial 
cultures, in tooth development, and the late stage of osteoclastogenesis87, 104. In osteoclasts, 
RvE1 has no effects on early osteoclast differentiation, but inhibits osteoclast fusion 105. On 
the other hand, chemerin increases osteoclast activity in vitro, and this is abrogated by the 
ChemR23 antagonist CCX832106. Moreover, antibody neutralization of chemerin inhibits 
osteoclast differentiation and mineralized matrix resorption 107. Taking all into account, 
ChemR23 appears to have a key role in cell fate, especially in bone development as well as 
VSMCs phenotypical differentiation. 
1.4 Clinical Determination of Calcification 
Multidetector computed tomography (CT) can be used to assess coronary artery calcification 
(CAC) and aortic valve calcification 108. To quantify calcification different scoring methods 
have been developed. The standard methodology for CAC assessment is the Agaston score, 
calculated multiplying the calcified area, defined as an area with a peak intensity >130 
Housenfield units (HU) within a 3mm slice, by a density factor. The density factor is based 
on the maximum HU within the area of interest 109. Apart from the Agatston score other 
measurements have been developed to closer mirror the physical properties of the calcified 
area. Firstly, the calcium volume, multiplies the area of calcification per slice, times the slice 
thickness and adds the volumes of all the slices with calcification. Unlike the Agatston score, 
the calcium volume measurement does not take the density into account. Secondly, the 
calcium mass score aims to determine the actual mass of hydroxyapatite within the calcified 
vessel by using phantom calibration and correction factors. Finally, the calcium density score 
is a combination of the Agatston score and the volume score, thus providing an average 
density of the whole area studied 110. CAC assessment by CT is of special importance for risk 
prediction of future cardiovascular events in asymptomatic individuals 111, 112.  As a matter of 
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fact, CAC volume is positively associated with cardiovascular disease (CVD) events, 
whereas CAC density shows a negative association 11, suggesting that a low CAC density 
might be associated with unstable atherosclerotic plaques.  Interestingly, in CKD patients, 
where calcification is mainly present in the medial layer, both CAC score and volume linearly 
predict mortality. However, CAC density presents an inverse J-shaped form, meaning CKD 
patients within the middle tertile of CAC densities present the highest mortality 113. Overall, 
this discrepancy between CKD and non-CKD patients highlights the differences between 
medial and intimal calcification.  
Another way to measure calcification is by using positron emission tomography (PET). 
Unlike CT, PET provides information about the activity of a biological process. In 
calcification two tracers have been used: 18F-fluorodeoxyglucose (18F-FDG) and 18F-
sodium fluoride (18F-NaF). 18F-FDG is used to detect inflammation around atherosclerotic 
micro-calcifications. This tracer is taken up by cells with high glucose consumption and the 
myocardium, which can obscure the assessment of calcification. On the other hand 18F-NaF 
preferentially adsorbs to nascent microcalcifications rather than stabilized calcification and 
predicts disease progression in patients with calcification of the aortic valve, making it a very 
attractive alternative for the early study of calcification 114, 115. 
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2 AIMS 
The aim of this thesis is to elucidate the role of structural cell fate and ECM in the 
development of cardiovascular calcification. In particular, the specific aims are: 
I. To determine the role of ChemR23 and its ligands on VSMCs, and in CKD-associated 
calcification (Articles I & II).  
II. To elucidate the role of ChemR23 and omega-3 PUFAs on intimal hyperplasia and VSMC 
proliferation (Article III). 
III. To define the role of iron in relation to AS calcification and more specifically, the effects 
of iron in VIC phenotype and ECM deposition (Article IV). 
IV. To establish the role of first and second generation tyrosine kinase inhibitors in AVS, and 
their effects in VICs, in particular through interaction with collagen receptor tyrosine kinases. 
(Article V). 
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3 EXPERIMENTAL METHODOLOGY 
3.1 In Vivo Models of Calcification 
In order to study the mechanisms of vascular calcification different animal models can be 
used. The models of calcification can be divided into distinct groups: genetic, surgical, and 
pharmacological.  
Genetic deletion of inhibitors of calcification causes extensive vascular calcification. MGP 
knock-out mice develop lethal vascular calcification and cartilaginous metaplasia at a very 
early stage in life 37. At the same time deletion of eNPP1 causes vascular calcification, with 
normal serum and phosphate levels, as well as bone defects 116. Surprisingly, deletion of 
Fetuin-A, a liver derived glycoprotein that inhibits calcium phosphate crystal growth, only 
causes vascular calcification in combination with other stressors such as hyperlipidemia or 
hyperphosphatemia 117. Moreover, inhibition of key molecules in the homeostasis of 
phosphate also promote calcification. Klotho is an inhibitor of the Na/Pi co-transporter and 
acts as a co-receptor for fibroblast growth factor 23 (FGF23), thus promoting phosphaturia 
and directly inhibiting phosphate uptake by VSMCs. Klotho deficient mice develop 
hyperphosphatemia and, in turn, soft tissue calcification 29, 118. 
Surgical intervention has also been used to model the calcification observed in CKD patients. 
5/6 nephrectomy requires the surgical removal of 5/6th of the kidney, thus mimicking severe 
kidney disease. Within 24 weeks after 5/6 nephrectomy rats develop vascular calcification. 
Supplementation with high phosphorous or vitamin D3 reduces this time by 6 weeks 119. 
Unlike rats, calcification in mice is only consistent in ApoE-/- mice on a high fat diet, 10 
weeks after the nephrectomy 31, 54. Importantly, without an ApoE-/- background, nephrectomy 
of mice does not always promote calcification, regardless of a high phosphate diet 120. 
Vascular calcification can also be induced pharmacologically. An adenine rich (0.2%) diet, 
supplemented with phosphate (1.8%), induces mild medial calcification alongside reduced 
bone mineral density within two weeks, which exacerbates after 6 weeks 121. Warfarin causes 
calcification of the elastic lamellae of rats within two weeks of treatment, by inhibiting the 
recycling of vitamin-K, hence inhibiting the carboxylation of Gla proteins122. Although the 
model is highly effective at inducing calcification in rats, mice may require longer treatment 
123. Finally, high dose vitamin D3 injections subcutaneously causes rapid calcification and 
bone resorption in mice. High dose vitamin D3 also induce bone resorption by increasing 
osteoclastic activity and inhibiting osteoblast mineralization through the vitamin D receptor, 
124, 125 thus increasing calcium absorption in the intestine, decreasing calcium excretion and 
increasing calcium and phosphate resorption from bone. At the same time, vitamin D3 
promotes intestinal phosphate absorption by increasing NaPi-IIb transporters. Apart from the 
systemic effects, vitamin D3 has local effects in VSMCs, and can promote VSMC 
osteoblastic trans-differentiation 126. 
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In the current thesis we used the Vitamin D3 model of calcification since it is a model which 
consistently induces rapid hyperphosphatemia and medial calcification in a VSMC relevant 
manner, without the need of complex surgical interventions or dietary supplementation. 
3.2 In Vitro Models of Calcification 
In vitro calcification is a useful tool for the high throughput pharmacological screening and 
for mechanistic experiments. The two most widely used methods for in vitro calcification are 
the high phosphate model and the β-glycerophosphate model.  
The β-glycephosphate model is often used in combination with ascorbic acid and 
dexamethasone, and in occasions TGF- β. This model is based on the principle that TNAP, 
expressed by VSMCs and VICs, excises the glycerol moiety, thus increasing free phosphate 
in the cell culture media. While at the same time, ascorbic acid and dexamethasone promote 
collagen production 127. With this model, VSMCs and VICs calcify after approximately 21 
days. Notwithstanding that this model is useful for the study of TNAP-dependent 
calcification, ultrastructural analysis, of seemingly calcified nodules in porcine VICs revealed 
that these nodules only calcified in the outer surface, while the inner core was formed solely 
of collagen fibers 128. 
On the other hand, the high phosphate model is based on two principles. Firstly, phosphate 
can act as a signaling molecule promoting the osteoblastic transformation of cells 129. And 
secondly, at a certain concentration (2mM), in solution, calcium and phosphate crystals begin 
to precipitate within 5 days, and this precipitation is actively inhibited by cells. Moreover, 
only in the presence of live cells these calcium phosphate crystals are embedded in an organic 
amorphous matrix, resembling the structure of hydroxyapatite crystals 130. In the current 
thesis the latter method was chosen because it better resembles the hyperphosphatemia in 
CKD patients and presents reduced calcification time. 
3.3 Calcification Quantification 
To quantify cardiovascular calcification several methods have been used in the current thesis. 
For the analysis of histological sections from either mice or humans Alizarin Red and Von 
Kossa stainings were used. Alizarin Red is an anthroquinone dye which preferentially stains 
calcium ions, resulting in a red color. Complementarily, Von Kossa is a silver nitrate based 
method, where silver replaces calcium present in calcium salts, resulting in black deposits. 
The Von Kossa staining is normally not used alone in the determination of calcium deposits 
in the aortic valve, as the black stain can be easily confused with the dark pigmentation of 
melanocytes 131. 
To quantify calcification in a semi-quantitative manner several methods have been used. In 
vitro Alizarin Red staining was quantified by spectrophotometry following the extraction of 
the red dye with acetic acid 132. In the later studies the OsteoImage assay was used. This 
method specifically labels hydroxyapatite fluorescently, thus increasing the specificity and 
sensitivity in the determination of calcification. This assay is a good complement to the 
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Alizarin Red method, since not all the calcification formed in vitro is hydroxyapatite. Finally, 
the o-cresolphthalein complexone method is another detection method for calcium ions. This 
method requires the dissolution of calcium salts with a strong acid, giving rise to a purple 
color that can be quantified by spectrophotometry. One disadvantage of this method is that it 
quantifies total calcium, including intracellular calcium. However, this method is compatible 
with protein determinations, thus allowing the normalization of calcium to total protein, 
making it very useful for the determination of calcification in tissues ex vivo. 
3.4 In Vivo & In Vitro Models of Proliferation 
In order to assess proliferation of VSMCs and VICs different models have been used in the 
current thesis. In vitro, thymidine incorporation and WST-1 were used to assess proliferation. 
On the one hand, thymidine incorporation, quantifies the incorporation of tritiated thymidine 
(3H-Thy) in newly synthesized DNA. Making it useful for the quantification of replicating 
cells.  On the other hand, WST-1 is a tetrazolium salt that becomes cleaved by metabolically 
active cells, giving rise to formazan, a soluble molecule that can be quantified by 
spectroscopy.  In this case, WST-1 serves as a marker of cell viability, and acts as a surrogate 
marker of cell proliferation.  
In vivo the murine carotid ligation model was used. In this model the left common carotid 
artery is ligated (Article III, Figure 1A), giving rise to a thrombus and thus inducing 
macrophage and neutrophil infiltration, as well as VSMC proliferation under inflammatory 
conditions133. 
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4 RESULTS & DISCUSSION 
The current thesis comprises of five different articles, in which the role of VSMCs, VICs and 
the ECM in cardiovascular calcification have been studied.  
In this section, the most relevant findings of these five articles are summarized and discussed. 
This discussion will serve as a complement to the discussion present in the articles, as well as 
to contextualize them with each other.  
Article I aimed to establish the role of ChemR23 in VSMC fate and calcification. 
Exploratory gene expression analyses in epigastric arteries from CKD patients identified 
COL1A1 as an independent predictor of ChemR23 gene expression. Causality behind this 
correlation was confirmed analyzing Col1A1 gene and protein expression in murine VSMCs 
lacking ChemR23. Further comparison between wild-type (ChemR23+/+) and knock-out 
(ChemR23-/-) VSMCs revealed that ChemR23+/+ VSMCs proliferated more and were more 
prone to loss of contractile proteins in vitro than ChemR23-/-. This difference in VSMC 
phenotype was accompanied by increased expression of the calcification inhibitor OPG in 
ChemR23-/- VSMCs, which is in line with our results in macrophages 134. Nonetheless, this 
difference in OPG production did not appear to be the sole reason for the reduced 
calcification observed in ChemR23-/-  VSMCs (Article I, Figure 3 A), as antibody adsorption 
of OPG did not increase ChemR23-/-  VSMC calcification to the same degree as in 
ChemR23+/+ VSMCs (Article I, Figure 3 D). Another potential mechanism by which 
ChemR23-/- VSMCs were protected from phosphate-induced calcification is the reduced 
osteoblastic signaling observed in ChemR23-/- VSMCs. ChemR23-/- VSMCs presented 
reduced Runx2 expression levels, and more importantly, they were resistant to BMP-2 
induced SMAD 1/5/8 phosphorylation.  This decrease in SMAD signaling could explain the 
lower levels of Runx2, as BMP-2 can promote Runx2 expression 70. Interestingly, this 
difference in SMAD phosphorylation was independent of BMP2R or inhibitory SMADs 
expression (Article I, Supplementary Figure 1), suggesting a more upstream BMP-2 
inhibition, such as increased MGP production. These differences are particularly interesting 
in light of the results from Tang et al, which show increased BMP-2 expression in ChemR23-
/- ovaries as compared with ChemR23+/+, and propose ChemR23 signaling to increase BMP-4 
expression 135, although the mechanism remains elusive. Nonetheless, these results suggest a 
link between ChemR23 signaling and BMPs.  
It is worth noting that the differences observed in vitro, specifically on VSMC phenotype, 
ECM production and calcification, could be reproduced in vivo in a vitamin D3-induced 
mouse model of medial calcification. Interestingly, we also observed reduced bone mineral 
density in ChemR23-/- mice, suggesting that ChemR23 plays a role in the preservation of 
bone. As a matter of fact, ChemR23 deficiency has been linked to reduced testosterone levels 
in male mice, consequently leading to reduced bone mineral density 136. Moreover, in MSCs, 
ChemR23 deficiency favors adipogenesis over osteoblastogenesis 137, which to some extent, 
could explain the difference observed in vascular calcification in this study and the increase 
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in atherosclerosis that we reported in ChemR23-/-/ApoE-/-  mice 134. Finally, in Article I, the 
ChemR23 ligand, RvE1, could inhibit both VSMC calcification and BMP-2 gene expression 
through ChemR23 in vitro, without altering VSMC phenotype. In vivo, by introducing the 
Fat-1 transgene, we could show that endogenous production of omega-3 PUFAs resulted in a 
reduction in the inhibition of calcification as a result of ChemR23 deletion (Article I, 
Supplementary figure 2).  Overall, these experiments suggest that the previously observed 
effects of omega-3 PUFAs on vascular calcification, could in part be mediated through the 
inhibitory signaling of ChemR23 by RvE1.  
As mentioned previously, chemerin is the other ligand of ChemR23. However, chemerin has 
been associated with an increased cardiovascular risk 90 and with CKD 93. Paradoxically, 
despite this dismal associations, chemerin is associated with a survival advantage in incident 
dialysis patients 95 suggesting that these increases in chemerin, at least in CKD patients, 
might be protective. Therefore, based on our results from Article I on the role of ChemR23 
signaling and calcification, we hypothesized that chemerin was exerting its protective effects 
in CKD patients by inhibiting calcification through ChemR23. For that reason, and to further 
elucidate the role of the ChemR23 pathway in vascular calcification, in Article II we aimed 
to establish the predictive value of chemerin as a biomarker for coronary calcification and 
determine the effects of chemerin signaling, through ChemR23 in VSMC calcification.  
In Article II, we confirmed that CKD patients present higher levels of chemerin than healthy 
controls. Importantly, we showed that chemerin was inversely associated with CAC score, 
even after adjustment for confounders (Article II, Figure 1B). Moreover, we observed that 
chemerin was positively associated with circulating levels of Fetuin A and MGP. To assess 
the causality behind these associations we treated murine VSMCs with chemerin under 
calcifying conditions, observing a reduction in calcification in the chemerin treated cells. 
Mechanistically, we could show that chemerin reduced calcification and increased MGP 
expression through ChemR23. Overall, chemerin arises as a potential inhibitor of vascular 
calcification, which acts locally in VSMCs, directly inhibiting calcification and increasing 
MGP; and can act systemically increasing fetuin A.  
In summary, in Article I and Article II, ChemR23 arises as a determinant of VSMC 
synthetic phenotype, with increased proliferation, collagen production, and susceptibility to 
phosphate-induced osteoblastic trans-differentiation and medial calcification. This increase in 
calcification could be inhibited with the ChemR23 ligands RvE1 and chemerin. Importantly, 
this pathway appeared relevant for CKD, as chemerin was inversely associated with CAC 
score in a cohort of CKD patients. 
So far Article I and Article II have explored the role of ChemR23 in VSMCs under non-
inflammatory conditions. However, work from our laboratory has demonstrated that under 
inflammation and hypercholesterolemia, characteristic of ApoE-/- mice, ChemR23 deletion 
increases atherosclerotic plaque size 134 and consequently intimal calcification (Figure 2). 
This effect in atherosclerosis was mediated by macrophages which present increased oxidized 
low density lipoprotein (oxLDL) uptake and reduced phagocytosis. This difference in 
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macrophage phenotype could also explain why the atherosclerotic plaques were more 
calcified, especially, since macrophages stimulated with oxLDL express higher TNAP 138 and 
M2 macrophages inhibit VSMC calcification in vitro by increasing extracellular Ppi 139. 
Moreover, macrophages can phagocyte hydroxyapatite particles 140, 141, therefore a decrease 
in phagocytosis could potentially translate into a decrease in the clearance of calcium-
phosphate crystals. Another explanation for this difference in atherosclerosis and intimal 
calcification may depend on changes in the VSMC phenotype under inflammatory 
conditions. To test the latter hypothesis, in Article III, we used the carotid ligation model to 
induce intimal hyperplasia.  
Figure 2. Intimal calcification in 
ApoE-/- mice: Representative 
photomicrographs of Alizarin Red 
stained aortic roots from:               
A) ApoE-/-/ChemR23+/+                            
B) ApoE-/-/ChemR23-/- 
 
The aims of Article III were to establish the role of ChemR23 in VSMC proliferation under 
inflammation, and determine the downstream signaling of omega-3 PUFAs in intimal 
hyperplasia. Analysis of intimal hyperplasia after carotid ligation revealed that ChemR23 
deletion significantly increased intimal hyperplasia. Interestingly, increasing omega-3 
production by means of Fat-1 transgene led to a reduction of intimal hyperplasia in both 
ChemR23+/+ and ChemR23-/- mice (Article III, Figure 1B). This finding was surprising in 
light of another report showing that RvE1 supplementation inhibited wire-injury induced 
VSMC migration 142. However, the direct involvement of ChemR23 in vivo was not studied. 
Overall, our results suggest that in our model: RvE1 may signal through its other receptor, 
BLT1; that other lipid mediators, such as RvD1, could promote the inhibition of intimal 
hyperplasia 143; or that the beneficial effects of omega-3 PUFAs in intimal hyperplasia could 
be mediated through the free fatty acid receptor-4 144.  
At the same time, the genotype effect observed between ChemR23+/+ and ChemR23-/- in 
Article III, was in sharp contrast with the effects on proliferation observed in Article I, those 
reported by Liu et al silencing ChemR23 in VSMCs 100, and the reduction in intimal 
hyperplasia reported by Xiong et al after silencing chemerin 145. To clarify this dichotomy, 
we hypothesized that the differential effects observed between ChemR23+/+ and ChemR23-/- 
mice, after carotid ligation, were caused by differences in inflammation. 
Immunohistochemical analysis of total neutrophil and macrophage content revealed no 
significant differences between the genotypes (Article III, Supplementary Figure 1). 
However, in support of previous reports 146 147, gene expression analyses showed that 
ChemR23-/- macrophages were more pro-inflammatory. Functionally, this difference between 
ChemR23+/+ and ChemR23-/- macrophages resulted in VSMCs proliferating more when 
cultured with conditioned media derived from ChemR23-/- macrophages. These experiments 
revealed that the same receptor can exert both protective and deleterious effects depending on 
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the degree of inflammation.  In line with these results, chemerin can also exert pro or anti-
inflammatory effects depending on the type of proteolytic cleavage carried out by proteases, 
and secreted by macrophages 96. This differential, chemerin cleavage, could explain why 
some reports have observed increased proliferation with chemerin 102, and others a decrease 
148.  
In summary, Articles I, II and III demonstrate that ChemR23 acts as a dual-role receptor 
dependent on the cell type in which it is expressed, as well as the degree of inflammation. In 
VSMCs, in the absence of inflammation, ChemR23 promotes proliferation, ECM production, 
and phosphate-induced calcification. Moreover, ChemR23 deletion can revert this trans-
differentiation of VSMCs, and, akin to RvE1 and chemerin, inhibit phosphate-induced 
calcification. However, in macrophages, ChemR23 promotes the resolution of inflammation, 
and its deletion enhances atherosclerosis, as well as intimal hyperplasia. In conclusion, these 
articles suggest that while ChemR23 promotes the resolution of inflammation in 
macrophages, ChemR23 may transduce deleterious effects on VSMCs under non-
inflammatory conditions. 
 
Figure 3. Schematic summary of articles I, II & III: VSMC phenotype is altered by ChemR23. ChemR23 
promotes a synthetic phenotype prone to phosphate-induced calcification and osteoblastic signaling, this 
phenotype is reversed by the genetic deletion of ChemR23. The two ChemR23 ligands: RvE1 and chemerin 
decrease phosphate-induced calcification through ChemR23. Moreover, in a cohort of CKD patients, chemerin is 
associated with a reduced CAC score and an increase in the calcification inhibitors MGP and Fetuin-A. Finally, 
ChemR23 deletion enhances intimal hyperplasia and therefore VSMC proliferation through more inflammatory 
macrophages.  
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In Article IV, we hypothesized that the non-heme bound iron derived from extravasated red 
blood cells (RBC), from intraleaflet haemorrhages, initially described by Akahori et al 25,  
could be a driver of the progression of AVS. Based on this hypothesis, we aimed to establish 
the role of iron in relation to AVS calcification; more specifically, the effects of iron in VIC 
phenotype and ECM deposition.  
Stratification of 36 valves, from AVS patients, based on their iron positivity, measured by 
Pearl´s blue staining, revealed a positive association with the degree of calcification.  In 
addition, iron positivity correlated with MMP9 expression, suggesting an effect of iron on 
ECM degradation. As mentioned in the introduction, VICs are the most abundant cell type of 
the valve and their phenotypic transformation is considered a key driver in the progression of 
AVS. Two key cytokines involved in this process are tumor necrosis factor alfa (TNF-α), and 
TGF-β 149. Stimulation of VICs with these cytokines resulted in a decrease in expression of 
the iron exporter ferroportin (FPN1), while TNF-α stimulation also increased the expression 
of the divalent metal transporter (DMT1), an importer of iron. Suggesting, that VICs could 
uptake iron, and that relevant pathophysiological pathways can favor this uptake. In support 
of these results, VICs from control patients expressed significantly higher levels of FPN1.  
To understand if VICs were causally involved in the retention of iron in the calcified valves, 
we treated VICs with iron sulfate. These experiments revealed that VICs could, in a time-
dependent manner, take up iron. Finally, to determine whether iron can alter VIC phenotype, 
and thus contribute to the disease progression, we analyzed the effect of iron on VIC 
proliferation and elastin deposition. Iron significantly increased VIC proliferation. This 
switch from a quiescent state towards a proliferative one is one of the earlier stages in the 
disease 51, suggesting that iron could contribute to an increase in valve thickening. These 
results are in line with those observed in human hepatic carcinoma cells where iron promotes 
proliferation and chemerin inhibits this effect by downregulating DMT1 and transferrin 
receptors, leading to cell cycle arrest 148. In addition, in Article IV, iron significantly 
decreased elastin production. This decrease in elastin, accompanied by the observed increase 
in MMP9 in valves and our recently reported increase in cathepsin expression in the calcified 
tissue of human valves 80, support the role of iron as a potential modifier of the ECM in the 
valve, that can contribute to the progression of AVS. Importantly, building up on these 
results, a recent report has shown that early iron deposits are present in seemingly healthy 
areas, without alizarin red detectable calcification, of human aortic valves. The authors 
suggest that this iron comes from RBCs that permeate through the damaged endothelium; and 
that senescent RBCs can induce VIC osteoblastic signaling 24.  
In conclusion, Article IV demonstrates that iron accumulates in the VICs of the aortic valve, 
actively contributing to the ECM remodeling, VIC proliferation, and potentially osteoblastic 
trans-differentiation. 
In addition to elastin, another key structural component of the aortic valve is collagen. 
Recently, disrupted collagen sensing and content have risen as a potential mechanism in the 
development of vascular and valvular calcification, respectively 56, 58. Importantly, the 
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collagen sensing tyrosine kinase receptors DDR1 and 2 can be inhibited by the tyrosine 
kinase inhibitors (TKIs), clinically used in the treatment of chronic myeloid leukemia (CML). 
In Article V, based on the clinical observation of a young woman who developed rapid aortic 
stenosis progression upon initiation of nilotinib for the treatment of CML, we hypothesized 
that the second generation TKI nilotinib exerts detrimental effects in the valve through the 
inhibition of DDRs. Therefore, in Article V we aimed to establish the role of first and second 
generation TKIs in AVS, and determine the associated molecular mechanisms. Treatment of 
APOE*3Leiden.CETP transgenic mice with the first (imatinib) and second (nilotinib) 
generation TKIs revealed that nilotinib treated mice presented thicker valves than those 
treated with imatinib. An increase in valve thickness is one of the hallmarks in the initiation 
of AVS, and is associated with increased proliferation, ECM remodeling, and calcification.  
To discover the pathways behind nilotinib’s increase in valve thickness, we explored the gene 
expression levels of the tyrosine kinases (TKs), targeted by nilotinib, in the healthy and 
calcified tissue of human aortic valves.  Among all the TKs explored, only DDR2 was both 
among the highest expressed in healthy tissue and the most downregulated in calcified tissue. 
Importantly, in patients with renal disease, DDR2 was already downregulated in the 
thickened tissue. To determine if hyperphosphatemia (one of the key hallmarks of CKD) was 
involved in this premature downregulation of DDR2 we cultured VICs under calcifying 
conditions induced by high phosphate. This experiment revealed that phosphate reduced 
DDR2 expression in VICs, suggesting a direct role of phosphate in DDR2 downregulation.  
Further analyses in VICs, revealed that DDR2 was preferentially expressed over DDR1 and 
that only nilotinib inhibited both DDR1 and 2, whereas imatinib only inhibited DDR1. 
Importantly, in lung fibroblasts, Col1A1 signaling is dependent exclusively on DDR2 activity 
150, suggesting that this differential regulation of DDRs might be particularly important in the 
interplay between VICs and the ECM.  Moreover, treatment with nilotinib enhanced VIC 
calcification and promoted osteogenic signaling in VICs by increasing Runx2 and BMP-2 
expression. Finally, nilotinib significantly inhibited VIC autophagic flux.  
Overall, in Article V, our results show that in vivo nilotinib promotes aortic valve thickening, 
and in vitro nilotinib promotes VIC osteoblastic trans-differentiation and calcification. At the 
same time, nilotinib inhibits autophagy, a pathway involved in VIC osteoblastic trans-
differentiation, and survival. Moreover, we show that pathways relevant to collagen sensing 
are altered in AVS, with a preference for DDR2. This difference in DDR expression might be 
of particular relevance for the field of cardio-oncology, in light of the differential inhibition 
that first and second generation TKIs present for these receptors. 
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Figure 4. Schematic summary of articles IV & V: Iron from extravasated RBCs is taken up by VICs through 
DMT1, promoting VIC proliferation and a decrease in elastin production. The expression of the iron importer 
DMT1 is induced by TNF-α, whereas the expression of the iron exporter FPN1 is inhibited by both TNF-α and 
TGF-β. DDR2 is preferentially expressed over DDR1 in human aortic valves. The nilotinib inhibits both DDR1 
and 2 promoting an increase in the osteoblastic signaling, calcification and a decrease in autophagy.  
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5 SUMMARY & CONCLUSIONS 
In summary, four key findings arise from the current thesis: First, the GPCR, ChemR23 has 
profound effects in VSMC phenotype and ECM production, promoting a synthetic and 
proliferative phenotype, which translates into an increase in medial calcification under 
hyperphosphatemia. Importantly, this increase in calcification can be inhibited with the 
ChemR23 ligands RvE1 and chemerin. Secondly, under inflammation, ChemR23, expressed 
in macrophages, promotes the resolution of inflammation, thus inhibiting VSMC 
proliferation. Third, inorganic ions like iron, and not just phosphate and calcium, can modify 
the phenotype of VICs leading to ECM remodeling and consequently valvular calcification. 
Finally, inhibition of the ECM sensing, by the TKI nilotinib, can promote valve thickening, 
VIC osteoblastic trans-differentiation and calcification. 
In conclusion, the ChemR23 pathway arises as a key determinant of a synthetic VSMC 
phenotype, contributing to vascular calcification. Importantly, both ChemR23 ligands, RvE1 
and chemerin, inhibited calcification through ChemR23, thus revealing ChemR23 as a 
pharmacologically relevant pathway for cardiovascular calcification. At the same time, in the 
aortic valve, alterations in the ECM appear as both a cause and a consequence in the 
phenotypic trans-differentiation of VICs leading to AVS. 
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